† These authors contributed equally to the project.
Introduction
Gd(III) complexes are widely used in medicine. They are extensively used as diagnostic agents in magnetic resonance imaging (MRI) as water relaxation agents to improve the image contrast, [1] [2] [3] but Gd(III) complexes have more recently shown potential as therapeutic agents.
The archetypal example of a therapeutic Gd(III) agent is Motexafin-Gd (MGd), which underwent Phase I/II clinical trials as a radiosensitiser in the treatment of lung tumour metastases to the brain by means of whole-brain radiotherapy until the FDA stopped further clinical trials with this agent in late 2007. [4] [5] [6] [7] [8] [9] However, Gd(III) complexes can indeed offer intriguing new avenues for cancer research with respect to binary therapies. Notable examples of binary cancer therapies include neutron capture therapy (NCT) [10] [11] [12] [13] [14] and photon activation therapy (PAT). 7, 9 Both GdNCT and GdPAT are dependent on the production of the high linear-energy transfer Auger Coster-Krönig (ACK) electrons which result from the thermal neutron capture or photon activation reactions of the f-block element (or more specifically, in the case of NCT, the non-radioactive and naturally-occurring 157 Gd isotope).
Due to the extremely short path-length (ca. 12nm) exhibited by ACK electrons, 15 the development of tumour-selective Gd agents which are localised nearby important macromolecules such as DNA or sub-cellular organelles such as mitochondria is critical. [10] [11] [12] [13] [14] Recently, both sub-cellular components have been successfully targeted by Gd(III). 10, 16 The first example of a Gd(III)-Pt(II) DNA metallointercalator which was found to selectivelydeliver Gd(III) to A459 lung tumour cell nuclei was reported in 2010 by Crossley, et al. 10 Herein, we present the next generation of DNA metallointercalators which addresses three unfavourable key factors associated with the prototype Gd(III)-Pt(II) complex: i) improved hydrolytic stability by the introduction of the macrocyclic DO3A ligand instead of the acyclic DTPA (diethylenetriaminepentaacetato) ligand, ii) decreased cytotoxicity in the absence of external X-ray photons or thermal neutrons by reducing the number of [Pt II (terpy)] 2+ (terpy = 2,2':6',2"-terpyridine) units from two to one, and iii) increased cellular uptake by lowering the overall charge of the complex from +2 to +1. The modular synthetic strategy reported herein will also allow for the preparation of a family of related potential Gd(III) agents for potential application in GdNCT and GdPAT.
Results and Discussion

Synthesis
The target complex 1•PF6 was successfully synthesised as outlined in Scheme 1.
<Insert Scheme 1 here>
The t Bu-protected macrocycle DO3A-t Bu3 was synthesised according to the method developed by Moore and Patterson. 17 The synthesis of the linker unit first involved the protection of the thiol group in cysteamine with a triphenylmethane (trityl) group, as described by Gale, et al. 18 The synthesis of N-(2-bromoacetyl)-triphenylmethyl-cysteamine was carried out by using a modified procedure developed by O'Neil, et al. 19 whereby the bromoacetylation was conducted at -78 °C in a dry-ice/acetone bath with very slow dropwise addition of trityl-cysteamine.
The macrocycle DO3A-t Bu3 was then derivatised by using the trityl-protected thiol linker group under basic conditions in acetonitrile whilst maintaining the reaction temperature of the reaction mixture at 70°C for 5 hours. Under these optimised reaction conditions, the yield of the protected trityl-DO3A-t Bu3 (2) was significantly improved in comparison with that of the reported synthetic protocol. 20 The global deprotection of 2 was carried out in a 1:1 solution of TFA/propanethiol in the presence of triethylsilane to yield the thiol-DO3A (3). Deprotection of a trityl group to a thiol functionality is often reversed by re-substitution of the trityl group, resulting in low yields of the desired product. 21 In order to improve the yield of the desired products, triethylsilane and excess propanethiol were used, acting as trityl group deactivator and tert-butyl scavenger, respectively. 21, 22 The final step of the synthesis involved the complexation to the two metal ions, Pt(II) and
Gd(III). The chlorido ligand in [Pt(terpy)Cl] + is a reasonable leaving group and can be readily substituted by thiolato ligands in aqueous solution. 23 A one-pot synthesis employing both 
Characterisation of 1·PF6
High resolution ESI-MS was used to confirm the identity of 1•PF6. Due to several naturallyoccurring isotopes of both Pt and Gd, the isotopic envelope is quite pronounced and the molecular ion peak is very distinctive. The theoretically calculated and experimentally determined ESI-MS ( Figure S1 ) were in very good agreement with the most intense peak attributed to [M+H] + observed at m/z of 1044.16286 (Calc. m/z 1044.16155). The purity of 1•PF6 was confirmed by elemental analysis and full details are given in the experimental section. Unfortunately, despite repeated attempts, crystals of 1•PF6 which were suitable for X-ray diffraction could not be obtained.
In Vitro Cytotoxicity Study
The in vitro cytotoxicity of 1•PF6 was assessed by means of a standard MTT assay protocol by using a human glioblastoma (T98G) cell line. The IC50 value was determined to be 31.3 ± 0.7 µM which demonstrates a significantly lower cytotoxicity compared to that of the prototype DNA-targeted Gd(III)-Pt(II) agent or MGd. 8, 10 Interestingly, the relative cell viability in the presence of 1•PF6 did not significantly decrease further, even at the highest concentration (250 µM) a relative cell viability of 43.1 ± 0.5 % was observed ( Figure S2 ). This unusual trend is possibly the result of strong non-covalent (π-π) stacking interactions between 1 + cations in aqueous solution which might lead to a reduced cellular uptake at higher concentrations of complex due to the formation of dimers and higher-order aggregates, as has been observed previously with other Pt(II)-terpy complexes. 24
Preliminary DNA-Binding Study
Linear Dichroism (LD) is a measure of the absorption difference between linearly and perpendicularly polarised light. [25] [26] [27] [28] Unless the system in question has inherent anisotropy orientation, certain techniques are required to introduce anisotropy in samples in order to measure their LD spectrum. Orientation techniques include squeezed gel methods, electric field orientation and flow techniques. Large macromolecules such as DNA (>1000 basepairs) can be easily oriented by the flow techniques using a flow couette cell, which was exclusively used in this study. 25 The non-covalent binding interaction between 1•PF6 and calf-thymus (ct) DNA was investigated by recording the LD spectrum of a ct-DNA solution with increasing present. An important trend observed was the increase in the negativity of the LD signal at 260 nm, providing evidence that the ct-DNA was becoming more oriented in flow upon the addition of 1•PF6. This result is consistent with an intercalative binding mode by 1•PF6, 26 whereby the non-covalent insertion of the Pt(II)-terpy intercalator between the DNA basepairs causes the ct-DNA to lengthen and stiffen. It should also be noted that an induced LD signal was observed in the 310-360 nm region. This negative signal was found to increase with increasing concentration of 1•PF6. The negative LD signal qualitatively provides an indication of the angle of binding of 1•PF6 to ct-DNA, indicating a perpendicular transition moment of the complex to the axis of polarisation. The signal in this range is most likely associated with an electronic transition within the terpy ligand (π→π*, 306-350 nm). 29 As π→π* transition moments are polarised along the plane of an aromatic system, the LD spectra in Figure 1 shows that the terpy ligand of 1•PF6 must be co-planar with the ct-DNA bases and approximately perpendicular to the ct-DNA axis. These preliminary DNA binding studies provide strong evidence of an intercalative binding interaction between 1•PF6 and ct-DNA and, therefore, DNA intercalation is the dominant binding mode at a complex-to-base pair ratio of 1:1. 
Conclusion
Experimental
Materials and Methods: Distilled water was used in all experiments requiring this solvent.
Anhydrous CH2Cl2 was dried by freshly distilling from calcium hydride according to the procedures reported by Armarego and Chai. 30 All other solvents were used without prior purification. The macrocycle DO3A-t Bu3 was synthesised according to the method developed by Moore and Patterson. 17 The synthesis of triphenylmethyl cysteamine hydrochloride (Trityl-cysteamine hydrochloride) was carried out as described by Gale, et al. 18 All precursor chemicals were commercially available. Triethylenetetraamine (TETA) was purchased from Alfa Aesar and all other chemicals were purchased from the Sigma-Aldrich Chemical
Company. An exceptions is [Pt(terpy)Cl]Cl . 2H2O which was prepared by the method described by Lowe and Vilaivan. 31 Human glioblastoma multiforme (T98G) cells were maintained as monolayers in minimum essential medium supplemented with 10% fetal 
Biological Assays:
The in vitro cytotoxicity of 1•PF6 was assessed using the 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 32, 33 Briefly, cells were harvested with trypsin (0.1% v/v), and cell pellets were isolated by centrifugation. Cells were then re-suspended to a single cell suspension, cell numbers were counted using a haemocytometer (Weber), and then cells were seeded (density 1 × 10 4 cells per well) in growth medium (100 μL) using 96-well plates and were allowed to adhere overnight at 37 °C. The corresponding IC50 value for 1•PF6 was determined at the dose required to induce a 50% decrease in cell viability. All experiments were conducted in quadruplicate and the IC50 value is reported with a standard error. N-(2-bromoacetyl) -triphenylmethyl-cysteamine: The compound was synthesised by using a modified procedure reported by O'Neil et al. 19 Trityl cysteamine hydrochloride (1.50 g, 4.21 mmol) and triethylamine were dissolved in CH2Cl2 (10 mL). The solution was added dropwise to a stirred solution of bromoacetyl bromide (0.4 mL, d 2.32, 4.59 mmol) in CH2Cl2 (4 mL) at -78 °C. The reaction mixture was then allowed to warm to room temperature and it was then quenched with water (15 mL). CH2Cl2 (20 mL) was added and the organic layer was extracted and washed with 1 M HCl (1 × 20 mL), water (1 × 20 mL), NaHCO3 (saturated, 1 × 20 mL) and brine (1 × 20 mL). The organic layer was dried over Na2SO4 and concentrated to a volume of 10 mL. Addition of n-hexane (45 mL) resulted 9 in the formation of colourless crystals that were filtered off and washed with cold n-hexane (3 × 5 mL) to yield the desired product (1.55 g, 84 %). 1 -tert-butyl-2,2',2''-(10-(2-oxo-2-((2-(tritylthio)ethyl)amino)ethyl)-1,4,7,10tetraazacyclododecane-1,4,7-triyl) 2,2',2''-(10-(2-((2-mercaptoethyl) (2,2',2''-(10-(2-((2-mercaptoethyl)amino)-2-oxoethyl)-1,4,7,10tetraazacyclododecane-1,4,7-triyl)triacetato-N,N',N",N'",O,O',O") 
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